Chapter 19: Problem 3
An unapproved form of gene therapy, known as enhancement gene therapy, can create considerable ethical dilemmas. Why?
Chapter 19: Problem 3
An unapproved form of gene therapy, known as enhancement gene therapy, can create considerable ethical dilemmas. Why?
All the tools & learning materials you need for study success - in one app.
Get started for freeWhat are the different genetic markers that genome-wide association studies (GWAS) employ? How can scientists use this data to calculate the disease risk associated with each variation?
As genetic testing becomes widespread, medical records will contain the results of such testing. Who should have access to this information? Should employers, potential employers, or insurance companies be allowed to have this information? Would you favor or oppose having the government establish and maintain a central database containing the results of individuals' genome scans?
Following the tragic shooting of 20 children at a school in Newtown, Connecticut, in 2012 , Connecticut's state medical examiner requested a full genetic analysis of the killer's genome. What do you think investigators might be looking for? What might they expect to find? Might this analysis lead to oversimplified analysis of the cause of the tragedy?
Dominant mutations can be categorized according to whether they increase or decrease the overall activity of a gene or gene product. Although a loss-of- function mutation (a mutation that inactivates the gene product) is usually recessive, for some genes, one dose of the normal gene product, encoded by the normal allele, is not sufficient to produce a normal phenotype. In this case, a loss-of-function mutation in the gene will be dominant, and the gene is said to be haploinsufficient. A second category of dominant mutation is the gain-of- function mutation, which results in a new activity or increased activity or expression of a gene or gene product. The gene therapy technique currently used in clinical trials involves the "addition" to somatic cells of a normal copy of a gene. In other words, a normal copy of the gene is inserted into the genome of the mutant somatic cell, but the mutated copy of the gene is not removed or replaced. Will this strategy work for either of the two aforementioned types of dominant mutations?
A couple with European ancestry seeks genetic counseling before having children because of a history of cystic fibrosis (CF) in the husband's family. ASO testing for CF reveals that the husband is heterozygous for the \(\Delta 508\) mutation and that the wife is heterozygous for the \(R 117\) mutation. You are the couple's genetic counselor. When consulting with you, they express their conviction that they are not at risk for having an affected child because they each carry different mutations and cannot have a child who is homozygous for either mutation. What would you say to them?
What do you think about this solution?
We value your feedback to improve our textbook solutions.